

**Oklahoma Health Care Authority  
Drug Utilization Review Board  
(DUR Board)  
Meeting –April 10, 2013 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. March 13, 2013 DUR Minutes – Vote
  - B. March 14, 2013 DUR Recommendation Memorandum
  - C. Correspondence

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Medication Coverage Activity for March 2013
  - B. Pharmacy Help Desk Activity for March 2013
  - C. Retrospective Drug Evaluation: Focusing on Safety

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

5. **Action Item - Vote to Prior Authorize Juvisync<sup>®</sup>, Bydureon<sup>®</sup>, Jentadueto<sup>®</sup>, Janumet XR<sup>®</sup>, Nesina<sup>®</sup>, Kazano<sup>®</sup>, and Oseni<sup>®</sup> – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

6. **Action Item – Vote to Prior Authorize Eliquis<sup>®</sup> and to Update Xarelto<sup>®</sup> Prior Authorization Criteria– See Appendix D.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Kuvan<sup>®</sup> – See Appendix E.**  
A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Vote to Prior Authorize Gattex<sup>®</sup> – See Appendix F.**  
A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **Action Item - Vote to Prior Authorize Kynamro<sup>™</sup> and to Update Juxtapid<sup>™</sup> Prior Authorization Criteria – See Appendix G.**  
A. Background  
B. Product Summaries  
C. Cost Comparison  
D. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

10. **Action Item – Intervention Strategies for Reduction of Narcotic Overprescribing – See Appendix H.**  
A. Prescriber Survey  
B. Narcotic Prescriber Profiling  
C. Quantity Limit Reduction  
D. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

11. **Fiscal Year 2012 Annual Review – See Appendix I.**  
A. Top 100 Drugs by Reimbursement  
B. Top 50 Drugs by Total Number of Claims  
C. Expenditures by Therapeutic Class

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

12. **FDA and DEA Updates – See Appendix J.**

13. **Future Business**  
A. May 2013 Meeting Cancelled  
B. New Product Reviews  
C. Annual Reviews

14. **Adjournment**